Bio-Techne Co. (NASDAQ:TECH) Director Alpna Seth sold 5,023 shares of the firm’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $306.62, for a total value of $1,540,152.26. Following the completion of the sale, the director now directly owns 4,037 shares in the company, valued at approximately $1,237,824.94. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of TECH stock opened at $304.90 on Friday. The business has a 50-day moving average of $273.96 and a 200 day moving average of $263.21. The company has a debt-to-equity ratio of 0.25, a current ratio of 4.88 and a quick ratio of 3.92. Bio-Techne Co. has a 1-year low of $155.17 and a 1-year high of $316.87. The stock has a market capitalization of $11.77 billion, a PE ratio of 52.66, a P/E/G ratio of 7.83 and a beta of 0.98.

Bio-Techne (NASDAQ:TECH) last released its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $1.43 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.33. Bio-Techne had a return on equity of 11.94% and a net margin of 31.04%. The firm had revenue of $204.20 million during the quarter, compared to analyst estimates of $185.04 million. During the same quarter in the prior year, the firm posted $1.06 earnings per share. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. Analysts anticipate that Bio-Techne Co. will post 4.83 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 27th. Shareholders of record on Monday, November 16th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.42%. The ex-dividend date is Friday, November 13th. Bio-Techne’s payout ratio is 33.16%.

Several institutional investors have recently bought and sold shares of TECH. Summit X LLC bought a new stake in shares of Bio-Techne in the third quarter worth about $25,000. First Horizon Advisors Inc. lifted its holdings in Bio-Techne by 28.9% in the 3rd quarter. First Horizon Advisors Inc. now owns 156 shares of the biotechnology company’s stock worth $38,000 after buying an additional 35 shares during the period. Signaturefd LLC grew its position in shares of Bio-Techne by 19.1% in the 2nd quarter. Signaturefd LLC now owns 249 shares of the biotechnology company’s stock worth $66,000 after buying an additional 40 shares during the last quarter. Flagship Harbor Advisors LLC increased its stake in shares of Bio-Techne by 393.3% during the third quarter. Flagship Harbor Advisors LLC now owns 296 shares of the biotechnology company’s stock valued at $73,000 after buying an additional 236 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Bio-Techne during the second quarter valued at approximately $75,000. Institutional investors own 94.49% of the company’s stock.

Several research analysts recently weighed in on TECH shares. KeyCorp initiated coverage on shares of Bio-Techne in a research report on Monday, November 9th. They issued a “sector weight” rating and a $340.00 price objective on the stock. Zacks Investment Research cut shares of Bio-Techne from a “hold” rating to a “sell” rating in a research report on Tuesday, October 6th. Robert W. Baird upped their target price on shares of Bio-Techne from $289.00 to $320.00 and gave the stock an “outperform” rating in a research report on Friday, November 6th. Wells Fargo & Company reissued a “hold” rating on shares of Bio-Techne in a research note on Tuesday, August 4th. Finally, BidaskClub raised Bio-Techne from a “sell” rating to a “hold” rating in a research note on Friday, October 16th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $297.55.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies.

Recommended Story: Example of operating income, EBIT and EBITDA

Insider Buying and Selling by Quarter for Bio-Techne (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with's FREE daily email newsletter.